Login / Signup

A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors.

Rémi VernetEugenio FernandezDenis MiglioriniVirginie AncrenazEmily CharrierMarie-Claude BelkouchOlivier Von RohrMuriel UrwylerClaudio deVitoJessica RenauxJean VillardOlivier RubinJulien GroggNicolas Mach
Published in: Cancer research communications (2024)
This first-in-human phase I study introduces a groundbreaking approach to personalized cancer immunotherapy, addressing limitations of traditional strategies. By combining autologous irradiated tumor cells as a source of patient-specific antigens and utilizing encapsulated cell technology for localized, sustained delivery of granulocyte-macrophage colony-stimulating factor as an adjuvant, the study shows a very good safety and feasibility profile. This innovative approach holds the promise of addressing tumor heterogeneity by taking advantage of each patient's antigenic repertoire.
Keyphrases
  • endothelial cells
  • single cell
  • cell therapy
  • early stage
  • stem cells
  • case report
  • bone marrow
  • clinical trial
  • peripheral blood
  • artificial intelligence
  • platelet rich plasma